Jeil Pharma Holdings Inc (002620.KS)
KRW 7330.0
(-0.95%)
KRW 7330.0
(-0.95%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 125.28 Billion KRW | 10.61% |
| 2022 | 113.26 Billion KRW | -0.86% |
| 2021 | 114.24 Billion KRW | -7.98% |
| 2020 | 124.15 Billion KRW | 28.28% |
| 2019 | 96.78 Billion KRW | -0.8% |
| 2018 | 97.56 Billion KRW | 1459.67% |
| 2017 | 6.25 Billion KRW | -92.22% |
| 2016 | 80.45 Billion KRW | 9.28% |
| 2015 | 73.62 Billion KRW | 25.27% |
| 2014 | 58.77 Billion KRW | -7.61% |
| 2013 | 63.61 Billion KRW | -4.97% |
| 2012 | 66.94 Billion KRW | 2.05% |
| 2011 | 65.59 Billion KRW | 14.43% |
| 2010 | 57.32 Billion KRW | 24.42% |
| 2009 | 46.07 Billion KRW | -39.06% |
| 2008 | 75.6 Billion KRW | 20.97% |
| 2007 | 62.49 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 133.69 Billion KRW | 0.68% |
| 2024 Q1 | 132.78 Billion KRW | 5.99% |
| 2023 Q2 | 132.6 Billion KRW | 0.12% |
| 2023 Q1 | 132.44 Billion KRW | 16.93% |
| 2023 FY | 125.28 Billion KRW | 10.61% |
| 2023 Q4 | 125.28 Billion KRW | -11.29% |
| 2023 Q3 | 141.22 Billion KRW | 6.5% |
| 2022 Q2 | 111.36 Billion KRW | 3.01% |
| 2022 Q1 | 108.11 Billion KRW | -5.37% |
| 2022 FY | 113.26 Billion KRW | -0.86% |
| 2022 Q4 | 113.26 Billion KRW | -0.23% |
| 2022 Q3 | 113.52 Billion KRW | 1.94% |
| 2021 Q3 | 113.97 Billion KRW | -5.2% |
| 2021 Q4 | 114.24 Billion KRW | 0.24% |
| 2021 FY | 114.24 Billion KRW | -7.98% |
| 2021 Q1 | 122.55 Billion KRW | -1.29% |
| 2021 Q2 | 120.22 Billion KRW | -1.9% |
| 2020 Q4 | 124.15 Billion KRW | -5.32% |
| 2020 Q2 | 121.61 Billion KRW | 8.56% |
| 2020 Q3 | 131.12 Billion KRW | 7.82% |
| 2020 FY | 124.15 Billion KRW | 28.28% |
| 2020 Q1 | 112.02 Billion KRW | 15.75% |
| 2019 Q2 | 92.4 Billion KRW | -8.73% |
| 2019 Q4 | 96.78 Billion KRW | 6.83% |
| 2019 Q1 | 101.24 Billion KRW | 3.77% |
| 2019 Q3 | 90.59 Billion KRW | -1.96% |
| 2019 FY | 96.78 Billion KRW | -0.8% |
| 2018 Q2 | 7.78 Billion KRW | 18.55% |
| 2018 Q3 | 9 Billion KRW | 15.73% |
| 2018 FY | 97.56 Billion KRW | 1459.67% |
| 2018 Q1 | 6.56 Billion KRW | 4.93% |
| 2018 Q4 | 97.56 Billion KRW | 983.37% |
| 2017 Q1 | 84.87 Billion KRW | 5.5% |
| 2017 Q2 | 6.58 Billion KRW | -92.24% |
| 2017 FY | 6.25 Billion KRW | -92.22% |
| 2017 Q3 | 6.01 Billion KRW | -8.62% |
| 2017 Q4 | 6.25 Billion KRW | 3.99% |
| 2016 FY | 80.45 Billion KRW | 9.28% |
| 2016 Q4 | 80.45 Billion KRW | 0.0% |
| 2015 Q2 | 67.54 Billion KRW | 6.04% |
| 2015 FY | 73.62 Billion KRW | 25.27% |
| 2015 Q3 | 69.97 Billion KRW | 3.6% |
| 2015 Q1 | 63.69 Billion KRW | 8.38% |
| 2014 Q1 | 58.25 Billion KRW | -8.43% |
| 2014 Q2 | 55.3 Billion KRW | -5.07% |
| 2014 Q3 | 56.17 Billion KRW | 1.59% |
| 2014 Q4 | 58.77 Billion KRW | 4.62% |
| 2014 FY | 58.77 Billion KRW | -7.61% |
| 2013 Q3 | 62.23 Billion KRW | 2.84% |
| 2013 Q4 | 63.61 Billion KRW | 2.21% |
| 2013 Q2 | 60.51 Billion KRW | 2.22% |
| 2013 Q1 | 59.2 Billion KRW | -11.56% |
| 2013 FY | 63.61 Billion KRW | -4.97% |
| 2012 Q3 | 66.11 Billion KRW | -5.41% |
| 2012 Q2 | 69.89 Billion KRW | -5.33% |
| 2012 Q1 | 73.83 Billion KRW | 12.55% |
| 2012 FY | 66.94 Billion KRW | 2.05% |
| 2012 Q4 | 66.94 Billion KRW | 1.25% |
| 2011 FY | 65.59 Billion KRW | 14.43% |
| 2011 Q4 | 65.59 Billion KRW | 12.33% |
| 2011 Q3 | 58.39 Billion KRW | -6.85% |
| 2011 Q2 | 62.69 Billion KRW | 0.82% |
| 2011 Q1 | 62.18 Billion KRW | 8.47% |
| 2010 Q1 | 57.15 Billion KRW | 24.06% |
| 2010 Q2 | 58.05 Billion KRW | 1.57% |
| 2010 FY | 57.32 Billion KRW | 24.42% |
| 2010 Q4 | 57.32 Billion KRW | 0.04% |
| 2010 Q3 | 57.3 Billion KRW | -1.3% |
| 2009 Q3 | 54.28 Billion KRW | -16.48% |
| 2009 Q2 | 65 Billion KRW | -13.55% |
| 2009 Q1 | 75.19 Billion KRW | -0.54% |
| 2009 FY | 46.07 Billion KRW | -39.06% |
| 2009 Q4 | 46.07 Billion KRW | -15.13% |
| 2008 Q1 | 67.54 Billion KRW | 8.07% |
| 2008 Q2 | 71.35 Billion KRW | 5.64% |
| 2008 Q4 | 75.6 Billion KRW | 8.93% |
| 2008 Q3 | 69.4 Billion KRW | -2.73% |
| 2008 FY | 75.6 Billion KRW | 20.97% |
| 2007 Q3 | 60.28 Billion KRW | 13.08% |
| 2007 FY | 62.49 Billion KRW | 0.0% |
| 2007 Q2 | 53.3 Billion KRW | 2.43% |
| 2007 Q4 | 62.49 Billion KRW | 3.67% |
| 2007 Q1 | 52.04 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | -77.207% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | -37.419% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -285.342% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | -6.303% |
| HANDOK Inc. | 94.46 Billion KRW | -32.621% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -160.305% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -102.966% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 33.589% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -286.856% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -313.735% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -132.33% |
| CKD Bio Corp. | 69.08 Billion KRW | -81.349% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | -48.044% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -183.746% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -256.148% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | -7.709% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 48.134% |
| Yuhan Corporation | 284.75 Billion KRW | 56.005% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -18.087% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -183.746% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -18.087% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 56.623% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -543.219% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -489.745% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -364.035% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | -57.382% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -159.125% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 35.676% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -18.087% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | -19.226% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -131.752% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 52.079% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -183.746% |
| Yuhan Corporation | 284.75 Billion KRW | 56.005% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -670.543% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -301.015% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | -102.108% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -154.935% |
| JW Holdings Corporation | 147.58 Billion KRW | 15.116% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 51.786% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | -14.132% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -132.33% |
| Boryung Corporation | 189.8 Billion KRW | 33.996% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -120.44% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -102.966% |
| JW Lifescience Corporation | 23.39 Billion KRW | -435.417% |